WO2001076557A1 - Preparations a liberation prolongee - Google Patents
Preparations a liberation prolongee Download PDFInfo
- Publication number
- WO2001076557A1 WO2001076557A1 PCT/JP2001/003024 JP0103024W WO0176557A1 WO 2001076557 A1 WO2001076557 A1 WO 2001076557A1 JP 0103024 W JP0103024 W JP 0103024W WO 0176557 A1 WO0176557 A1 WO 0176557A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sustained
- water
- preparation according
- release preparation
- layer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
Definitions
- the present invention relates to a pH-independent sustained-release preparation of a basic drug or a salt thereof having lower solubility in intestinal fluid than that in gastric fluid.
- the matrix is forced to be a single-unit formulation such as a tablet for controlled release, and coexistence with an acidic component is likely to impair the stability of the active ingredient in general.
- osmotic pumps JP-A-58-16259, etc.
- JP-A-58-16259, etc. are known as methods that can be applied more reliably to a wide range of drugs, but these require extremely complicated steps in production. Often needed.
- a technique of coating the inner core with a water-insoluble polymer and an enteric polymer in two layers Patent No. 265707) has been disclosed, but this technology allows selective elution in the intestine. This was achieved and was far from a formulation showing pH independent dissolution.
- the present inventors have conducted intensive studies to solve the above-mentioned problems, and as a result, a first layer composed of a sustained-release polymer and a second layer composed of an enteric polymer and a water-soluble polymer in an inner core containing a drug.
- the present invention is as follows.
- the sustained release characterized in that the inner core containing the drug is coated with 1) a first layer composed of a water-insoluble polymer, and 2) a second layer composed of an enteric polymer and a water-soluble polymer. Formulation.
- the enteric polymer of the second layer is hydroxypropylmethylcellulose acetate, hydroxypropylmethylcellulose acetate succinate, carboxymethylethylcellulose, cellulose acetate phthalate, methyl methacrylate methyl copolymer, acrylic methacrylate
- the sustained-release preparation according to any one of [1] to [4], which is an acid ethyl copolymer
- sustained-release preparation according to any one of [1] to [10], which contains tandospirone, perospirone, arotinolol, SM-13349, SMP-114 or a salt thereof as a drug.
- the medicinal component is not particularly limited as long as it is intended for oral administration, but a drug showing lower solubility in intestinal fluid than in gastric fluid, that is, a basic drug or a salt thereof is particularly preferred.
- Highly useful drugs include, for example, anti-anxiety drugs such as flurazebam hydrochloride, alprazolam, tandospirone quinate, rilmazaphon hydrochloride, antihistamines such as dipheniravirine hydrochloride, chlorpheniramine maleate, cimetidine, isotipendil hydrochloride, and feneryphrine hydrochloride , Cardiovascular agents such as procarinamide hydrochloride, quinidine sulfate, isosorbide dinitrate, nicorandil, etc., hypertensive agents such as amlodipine besylate, difendipine, dicardipine hydrochloride, nilpadipine, arotinolol hydrochloride
- the first layer comprising a water-insoluble polymer and, if necessary, a water-soluble polymer is the inner layer of the film.
- the basic dissolution rate is adjusted in this layer, that is, the desired dissolution rate of the drug is achieved by adjusting the mixing ratio of the water-insoluble polymer and the water-soluble polymer and the total amount of the coating film. Do Things.
- the second layer composed of the enteric polymer and the water-soluble polymer forms the outer layer of the film, and this layer improves the difference in the dissolution rate between gastric fluid and intestinal fluid. That is, by adjusting the mixing ratio of the enteric polymer and the water-soluble polymer and the total amount of the coating film, the pH dependency of the dissolution rate of the drug is improved.
- the second layer reduces the rate of dissolution in gastric fluid but does not affect the rate of dissolution in intestinal fluid. Therefore, the enteric coating layer selects the difference in dissolution rate between gastric juice and intestinal fluid, which usually occurs when sustained release of a drug whose solubility is higher in gastric juice than in intestinal fluid, and selects only the dissolution rate in gastric juice. A pH-independent elution rate is achieved by reducing the pH.
- the weight ratio of the first-layer water-insoluble polymer to the water-soluble polymer can be used in the range of 1: 0 to 1: 2, but is particularly preferably in the range of 1: 0 to 1: 1.
- the weight ratio of the enteric polymer to the water-soluble polymer in the second layer can be used in the range of 1: 0.01-1: 2, but is particularly preferably in the range of 1: 0.05-1: 1.
- the weight ratio between the first layer and the second layer can be used in the range of 1: 0.01-1 to 1: 5, and particularly preferably in the range of 1: 0.1 to L: 2.
- a suitable plasticizer such as triethyl citrate, macrogol, sucrose fatty acid ester, glycerin, triacetin, etc.
- a coating process for the purpose of improving the film formation.
- an anti-adhesion agent such as talc or light caffeic anhydride in order to prevent aggregation of the preparation.
- the water-insoluble polymer is not particularly limited, but examples thereof include ethyl cellulose, aminoalkyl methacrylate copolymer, and cellulose acetate.
- ethyl cellulose is preferred.
- a so-called ethyl cellulose aqueous suspension manufactured by FMC
- FMC ethyl cellulose aqueous suspension
- water-soluble polymer examples include, but are not particularly limited to, hydroxypropylmethylcellulose, hydroxypropylcellulose, methylcellulose, polyvinylpyrrolidone, and polyvinyl alcohol.
- hydroxypropylmethylcellulose is preferred for the first layer and polyvinylpyrrolidone for the second layer.
- Enteric polymers include hydroxypropylmethylcellulose acetate, hydroxypropylmethylcellulose acetate succinate, carboxymethylethylcellulose, cellulose acetate fluorate, methyl methacrylate methyl methacrylate copolymer, methacrylate acrylate. Chill copolymer and the like.
- methacrylic acid acrylate copolymer is preferred.
- Methacrylic acid ethyl acrylate copolymer is obtained in a polysorbate 80 and aqueous sodium lauryl sulfate solution of methacrylic acid and ethyl acrylate, which is referred to as Methacrylic acid copolymer LD (manufactured by Laem Pharma).
- Methacrylic acid copolymer LD manufactured by Laem Pharma
- An emulsion of the copolymer is used.
- the sustained-release preparation of the present invention may contain, in addition to the above components, additives usually used in the field of preparation.
- lactose lactose, mannitol, erythritol, corn starch, potato starch, xylitol, sorbitol, trehalose, glucose, sucrose, talc, kaolin, calcium hydrogen phosphate, calcium sulfate, calcium carbonate, crystalline cellulose, sucrose / starch spherical granules, crystals
- Excipients such as cellulose (granules), binders such as polyvinyl alcohol, polyvinylpyrrolidone, hydroxypropylmethylcellulose, hydroxypropylcellulose, agar, gelatin, etc., magnesium stearate, magnesium stearate, calcium stearate, sodium stearyl fumarate, etc.
- Lubricants calcium carboxymethylcellulose, disintegrators such as low-substituted hydroxymethylcellulose, light caffeic anhydride Fluidizing agents, other colorants, flavoring, flavoring agents, preservatives, stabilizers, antistatic agents, and the like foaming agents.
- disintegrators such as low-substituted hydroxymethylcellulose, light caffeic anhydride Fluidizing agents, other colorants, flavoring, flavoring agents, preservatives, stabilizers, antistatic agents, and the like foaming agents.
- the drug-containing core (granules, fine granules or tablets) is manufactured by a general manufacturing method, for example, mixing the drug with additives such as ⁇ excipients, using a binder solution, fluid bed granulation, wet crushing.
- Granules or fine granules can be produced by a granulation method, extrusion granulation method, tumbling granulation method, tumbling fluidized bed granulation method, etc., and these granules or fine granules are compression-molded. It is also possible to produce tablets.
- the inner core when the inner core is made into a granular form, the crystalline cellulose (granules) or sucrose / starch spherical condyle particles are used as the nucleus, and the drug is mixed with a suitable excipient such as an excipient or a disintegrant while spraying a binder solution.
- a suitable excipient such as an excipient or a disintegrant
- spraying a binder solution By repeatedly sprinkling the mixture, a granular inner core having a uniform particle size can be produced.
- the coating of the first layer and the second layer can be performed by a general production method.
- first and second layers on the inner core surface by charging the inner core into a fluidized bed or a tumbling fluidized bed type coating device or a pan-type coating device, spraying a coating solution, and drying. it can.
- FIG. 1 is a diagram showing the results of a dissolution test of Comparative Example 1.
- FIG. 2 is a diagram showing the results of a dissolution test of Comparative Example 2.
- FIG. 3 is a diagram showing the dissolution test results of Example 1.
- Composition (1) 337.5 g (solid content: 101.25 g) of ethyl cellulose aqueous suspension hydroxypropyl methylcellulose 11.25 g
- Methacrylic acid copolymer LD 240 g solid content: 72 g
- Methacrylic acid copolymer LD 240 g solid content: 72 g
- Methacrylic acid copolymer LD 200 g solid content: 60 g
- Methacrylic acid copolymer LD 200 g solid content: 60 g
- Tandospirone citrate was converted from SM-13496 hydrochloride ((1R, 2S, 3R, 4S) -N-[(1R, ZI-
- composition (8) Ethyl cellulose aqueous suspension 100 g (solid content: 30 g) Hydroxypropyl methylcellulose 10
- Methacrylic acid copolymer LD 180 g solid content: 54 g
- Tandospirone citrate converted to SMP—114 (3- [lS-l-2-fluorobiphenyl-4-yl] eth y 1] -5- ⁇ [amino (morpho 1 in-4-yl) methylene] amino ⁇ isoxazole) 910 g of nuclear granules containing SMP-114 were obtained in the same manner as in Reference Example 1 except for the change (SMP-114 was produced by the method described in JP-A-11-240873) .
- Methacrylic acid copolymer LD 150 g solid content: 45 g
- Ethylcellulose aqueous suspension 90 gg ((solid 1 form: 27 g) hydroxypropylmethylcellulose 9 g
- Methacrylic acid copolymer LD 200 g solid content: 60 g
- Comparative Example 1 there was a remarkable difference in the dissolution rate between JP 1 solution and 2 solution.
- Comparative Example 2 only the dissolution start time of JP 1 solution was delayed, and the dissolution rate equivalent to JP 2 solution was Can not be obtained.
- Example 1 the elution rates of the first solution and the second solution in JP were almost equal, and a desired pH-independent elution pattern could be obtained.
- the present invention provides a drug exhibiting a pH-dependent solubility by making it pH-independent.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001246861A AU2001246861A1 (en) | 2000-04-10 | 2001-04-09 | Sustained release preparations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-107671 | 2000-04-10 | ||
JP2000107671 | 2000-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001076557A1 true WO2001076557A1 (fr) | 2001-10-18 |
Family
ID=18620632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/003024 WO2001076557A1 (fr) | 2000-04-10 | 2001-04-09 | Preparations a liberation prolongee |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001246861A1 (ja) |
WO (1) | WO2001076557A1 (ja) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005011682A1 (ja) * | 2003-08-04 | 2005-02-10 | Kyorin Pharmaceutical Co., Ltd. | 経口徐放性錠剤 |
WO2005032588A1 (ja) * | 2003-09-30 | 2005-04-14 | Kyowa Pharmaceutical Ind. Co.,Ltd. | 塩基性薬剤含有製剤 |
EP1623709A1 (en) * | 2003-04-30 | 2006-02-08 | Dainippon Sumitomo Pharma Co., Ltd. | Remedy for rheumatoid arthritis |
JPWO2005009999A1 (ja) * | 2003-07-29 | 2006-09-07 | 大日本住友製薬株式会社 | イミド化合物の製造方法 |
JPWO2005117886A1 (ja) * | 2004-06-01 | 2008-04-03 | 久光製薬株式会社 | 貼付剤 |
JP2009503011A (ja) * | 2005-08-05 | 2009-01-29 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 強いpH−依存性溶解性を有する活性成分についての持続されたpH−非依存性活性成分開放性を有する医薬形 |
CN1899287B (zh) * | 2006-07-19 | 2010-09-29 | 四川科瑞德制药有限公司 | 一种治疗焦虑症的缓释药物组合物及其制备方法 |
US8729085B2 (en) * | 2005-05-26 | 2014-05-20 | Dainippon Sumitomo Pharma Co., Ltd. | Pharmaceutical composition |
US20150018368A1 (en) * | 2012-02-13 | 2015-01-15 | Cadila Healthcare Limited | Process for preparing benzisothiazol-3-yl-piperazin-1-yl-methyl-cyclo hexylmethanisoindol-1,3-dione and its intermediates |
JP2015107977A (ja) * | 2010-08-11 | 2015-06-11 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 代謝型グルタミン酸5受容体(mGlu5)アンタゴニストの医薬組成物 |
JP2015107986A (ja) * | 2010-08-11 | 2015-06-11 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 代謝型グルタミン酸5受容体(mGlu5)アンタゴニストの医薬組成物 |
CN106176659A (zh) * | 2015-05-05 | 2016-12-07 | 四川科瑞德制药股份有限公司 | 一种坦度螺酮肠溶片及其制备方法 |
CN106344519A (zh) * | 2015-07-17 | 2017-01-25 | 四川科瑞德制药股份有限公司 | 一种坦度螺酮肠溶微丸及其制备方法和用途 |
JP2023504409A (ja) * | 2019-12-25 | 2023-02-03 | シーチュアン クレジット ファーマシューティカル カンパニー リミテッド | タンドスピロン医薬組成物及びその製造方法と使用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0239361A1 (en) * | 1986-03-27 | 1987-09-30 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
WO1991006291A1 (en) * | 1989-10-26 | 1991-05-16 | Nippon Shinyaku Co., Ltd. | Sustained release preparation |
-
2001
- 2001-04-09 AU AU2001246861A patent/AU2001246861A1/en not_active Abandoned
- 2001-04-09 WO PCT/JP2001/003024 patent/WO2001076557A1/ja active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0239361A1 (en) * | 1986-03-27 | 1987-09-30 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
WO1991006291A1 (en) * | 1989-10-26 | 1991-05-16 | Nippon Shinyaku Co., Ltd. | Sustained release preparation |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2004096230A1 (ja) * | 2003-04-30 | 2006-07-13 | 大日本住友製薬株式会社 | 関節リウマチ治療剤 |
EP1623709A4 (en) * | 2003-04-30 | 2007-09-05 | Dainippon Sumitomo Pharma Co | REMEDY FOR RHEUMATOID ARTHRITIS |
EP1623709A1 (en) * | 2003-04-30 | 2006-02-08 | Dainippon Sumitomo Pharma Co., Ltd. | Remedy for rheumatoid arthritis |
JPWO2005009999A1 (ja) * | 2003-07-29 | 2006-09-07 | 大日本住友製薬株式会社 | イミド化合物の製造方法 |
US8343544B2 (en) | 2003-08-04 | 2013-01-01 | Kyorin Pharmaceutical Co., Ltd. | Oral sustained-release tablet |
WO2005011682A1 (ja) * | 2003-08-04 | 2005-02-10 | Kyorin Pharmaceutical Co., Ltd. | 経口徐放性錠剤 |
WO2005032588A1 (ja) * | 2003-09-30 | 2005-04-14 | Kyowa Pharmaceutical Ind. Co.,Ltd. | 塩基性薬剤含有製剤 |
JP2005104914A (ja) * | 2003-09-30 | 2005-04-21 | Kyowa Yakuhin Kogyo Kk | 塩基性薬剤含有製剤 |
JPWO2005117886A1 (ja) * | 2004-06-01 | 2008-04-03 | 久光製薬株式会社 | 貼付剤 |
US9555027B2 (en) | 2005-05-26 | 2017-01-31 | Sumitomo Dainippon Pharma Co., Ltd. | Pharmaceutical composition |
US8729085B2 (en) * | 2005-05-26 | 2014-05-20 | Dainippon Sumitomo Pharma Co., Ltd. | Pharmaceutical composition |
US8883794B2 (en) | 2005-05-26 | 2014-11-11 | Sumitomo Dainippon Pharma Co., Ltd. | Pharmaceutical composition |
US9907794B2 (en) | 2005-05-26 | 2018-03-06 | Sumitomo Dainippon Pharma Co., Ltd | Pharmaceutical composition |
JP2009503011A (ja) * | 2005-08-05 | 2009-01-29 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 強いpH−依存性溶解性を有する活性成分についての持続されたpH−非依存性活性成分開放性を有する医薬形 |
CN1899287B (zh) * | 2006-07-19 | 2010-09-29 | 四川科瑞德制药有限公司 | 一种治疗焦虑症的缓释药物组合物及其制备方法 |
JP2015107977A (ja) * | 2010-08-11 | 2015-06-11 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 代謝型グルタミン酸5受容体(mGlu5)アンタゴニストの医薬組成物 |
JP2015107986A (ja) * | 2010-08-11 | 2015-06-11 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 代謝型グルタミン酸5受容体(mGlu5)アンタゴニストの医薬組成物 |
US20150018368A1 (en) * | 2012-02-13 | 2015-01-15 | Cadila Healthcare Limited | Process for preparing benzisothiazol-3-yl-piperazin-1-yl-methyl-cyclo hexylmethanisoindol-1,3-dione and its intermediates |
US9409899B2 (en) * | 2012-02-13 | 2016-08-09 | Cadila Healthcare Limited | Process for preparing benzisothiazol-3-yl-piperazin-1-yl-methyl-cyclo hexylmethanisoindol-1,3-dione and its intermediates |
CN106176659A (zh) * | 2015-05-05 | 2016-12-07 | 四川科瑞德制药股份有限公司 | 一种坦度螺酮肠溶片及其制备方法 |
CN106176659B (zh) * | 2015-05-05 | 2019-07-12 | 四川科瑞德制药股份有限公司 | 一种坦度螺酮肠溶片及其制备方法 |
CN106344519A (zh) * | 2015-07-17 | 2017-01-25 | 四川科瑞德制药股份有限公司 | 一种坦度螺酮肠溶微丸及其制备方法和用途 |
JP2023504409A (ja) * | 2019-12-25 | 2023-02-03 | シーチュアン クレジット ファーマシューティカル カンパニー リミテッド | タンドスピロン医薬組成物及びその製造方法と使用 |
Also Published As
Publication number | Publication date |
---|---|
AU2001246861A1 (en) | 2001-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU763309B2 (en) | Bioenhanced formulations comprising eprosartan in oral solid dosage form | |
US20230240994A1 (en) | Medicament-containing hollow particle | |
BR112020024269A2 (pt) | combinação farmacêutica, composição e formulação de combinação contendo ativador de glucoquinase e ativador de receptor ppar e métodos de preparação e usos dos mesmos | |
ZA200200344B (en) | Method for making granules with masked taste and instant release of the active particle. | |
WO2006070781A1 (ja) | 塩基性薬物又はその塩を含有するマトリックス型徐放性製剤およびその製造方法 | |
JP2005526738A (ja) | 低溶解度の薬物を経口投与するための投与剤形 | |
JP2001526213A (ja) | 経口医薬パルス放出剤形 | |
CN101977593A (zh) | 包含弱碱性药物以及有机酸的给药系统 | |
JP2019527700A (ja) | タムスロシン塩酸塩含有徐放性ペレットを含む、溶出率が制御された経口投与用薬剤学的製剤 | |
WO2001076557A1 (fr) | Preparations a liberation prolongee | |
JP2002526437A (ja) | アジテーション非依存性薬学的マルチプル−ユニット持効性製剤およびその製法 | |
JP2003528905A (ja) | スタブジン含有持続放出性ビーズ剤 | |
CA2806459A1 (en) | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists | |
JPWO2003043661A1 (ja) | 酸に不安定な生理活性化合物を含有する製剤組成物及びその製法 | |
JP4438268B2 (ja) | 薬物顆粒の製造方法、および薬物顆粒、ならびにそれを用いた医薬製剤 | |
JPH10152440A (ja) | 活性物質としてニフェジピンを含有する経口投与用調節放出医薬組成物 | |
RU2602955C2 (ru) | Фармацевтические композиции антагонистов метаботропного глутаматного рецептора 5 (mglu5) | |
EP2533766A2 (en) | Pharmaceutical mini-tablets for sustained release of flecainide acetate | |
CA2374039C (en) | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations | |
JP2001522794A (ja) | カルベジロールの新規経口剤形 | |
WO2009014372A2 (en) | Dispersible tablet comprising coated drug-containing particles and method for the preparation thereof | |
RU2727721C2 (ru) | Фармацевтическая композиция с замедленным высвобождением, содержащая ривастигмин | |
JP4808612B2 (ja) | アルキレンジオキシベンゼン誘導体を含む経口投与用組成物 | |
IE990406A1 (en) | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations. | |
JPH01313431A (ja) | ジルチアゼム・マイクロビーズ、その製法および徐放性医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 574075 Kind code of ref document: A Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase |